San Diego-based Viking Therapeutics marked by itself as a serious competitor in the weight loss drug sector in February soon after revealing promising facts from the mid-phase demo of experimental drug VK2735, which recommended it rivaled—and outperformed—Novo and Lilly drugs when offered like a weekly injection As well as in March the company